Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Jankovic, Joseph ^a   Adler, Charles H ^b   Charles, P David ^c   Comella, Cynthia ^d   Stacy, Mark ^e   Schwartz, Marc ^f   Sutch, Susan M ^g   Brin, Mitchell F ^h,i   Papapetropoulos, Spyridon ^h,j  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MedNet Solutions   (United States)

^g UBC Envision Group   (United States)

^h ALLERGAN INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ANAMNESIS; ARTICLE; CERVICAL DYSTONIA; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRODUCTIVITY; PROSPECTIVE STUDY; REGISTER; STUDY DESIGN; UNITED STATES; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); MIDDLE AGED; QUESTIONNAIRE; TORTICOLLIS;

BOTULINUM TOXINS, TYPE A; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; QUESTIONNAIRES; REGISTRIES; TORTICOLLIS;

EID: 80155123507     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-140     Document Type: Article

References (38)

1. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007, 13:411-416. 10.1016/j.parkreldis.2007.02.005, 17442609.
2. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 2008, 26(Suppl 1):23-42.
3. Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis--review of 220 patients. Can J Neurol Sci 1991, 18:143-151.
4. Camfield L, Ben-Shlomo Y, Warner TT. Impact of cervical dystonia on quality of life. Mov Disord 2002, 17:838-841. 10.1002/mds.10127, 12210891.
5. Jankovic J. Treatment of dystonia. Lancet Neurol 2006, 5:864-872. 10.1016/S1474-4422(06)70574-9, 16987733.
6. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004, 75:951-957. 10.1136/jnnp.2003.034702, 1739107, 15201348.
7. Tarsy D, Simon DK. Dystonia. N Engl J Med 2006, 355:818-829. 10.1056/NEJMra055549, 16928997.
8. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706. 10.1212/01.wnl.0000311389.26145.95, 18458230.
9. Jankovic J. Botulinum toxin. Encyclopedia of Movement Disorders 2010, 1:144-150. Oxford: Academic Press, Kompoliti K, Verhagen Metman L.
10. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011, 305:89-90. 10.1001/jama.2010.1937, 21205970.
11. Sheean G. Cervical dystonia: unresolved issues and future challenges. Neurol Clin 2008, 26(Suppl 1):66-76.
12. Brans JW, Aramideh M, Koelman JH, Lindeboom R, Speelman JD, Ongerboer de Visser BW. Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl. Neurology 1998, 51:815-819.
13. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992, 42:878-882.
14. Barbano RL. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve 2001, 24:1567-1568. 10.1002/mus.1185, 11745963.
15. Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 2001, 24:1568-1570. 10.1002/mus.1186, 11745964.
16. Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002, 249:842-846. 10.1007/s00415-002-0733-1, 12140667.
17. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia?. J Neurol Neurosurg Psychiatry 2002, 72:608-614. 10.1136/jnnp.72.5.608, 1737851, 11971047.
18. Skogseid IM, Malt UF, Røislien J, Kerty E. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 2007, 14:1129-1137. 10.1111/j.1468-1331.2007.01922.x, 17708754.
19. Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 2007, 22:95-100.
20. Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006, 67:2230-2232. 10.1212/01.wnl.0000249310.25427.f2, 17190951.
21. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 2001, 71:193-199. 10.1136/jnnp.71.2.193, 1737507, 11459891.
22. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998, 50:1461-1463.
23. Consky E, Lang A. Clinical assessments of patients with cervical dystonia. Therapy with Botulinum Toxin 1994, 211-237. New York: Marcel Dekker, Inc, Jankovic J, Hallett M.
24. Papapetropoulos S, Rosa K, Comella C, Boo LM, Brin MF. Validity and reliability of the Pictorial Spasmodic Torticollis Rating Scale (P-STRS). Neurology 2011, 76:A587.
25. Guy W, Bonato RR, . editors Manual for the ECDEU Assessment Battery 1976, Chevy Chase: National Institute of Mental Health, editors.
26. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113:9-19. 10.1016/j.pain.2004.09.012, 15621359.
27. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003, 106:337-345. 10.1016/j.pain.2003.08.001, 14659516.
28. Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, Hobart JC. Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology 2004, 63:1629-1633.
29. Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 2009, 24:1384-1387. 10.1002/mds.22622, 19441129.
30. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999, 66:612-616. 10.1136/jnnp.66.5.612, 1736353, 10209172.
31. Baizabal Carvallo J, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon 2011,
32. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991, 41:1088-1091.
33. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991, 6:119-126. 10.1002/mds.870060206, 2057004.
34. Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther 2005, 22:49-55. 10.1007/BF02850184, 15943222.
35. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010, 16:316-323. 10.1016/j.parkreldis.2010.03.002, 20359934.
36. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008, 23:510-517. 10.1002/mds.21724, 18098274.
37. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65:1423-1429. 10.1212/01.wnl.0000183055.81056.5c, 16275831.
38. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005, 20:1152-1160. 10.1002/mds.20531, 15954134.